Roche shareholders approve deal to buy Novartis's $20.7 billion stake_老虎社区_美港股上老虎

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

Reuters2021-11-26

ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said. Roche held an ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

sharonyeo
·2021-11-26
Hi
回复
点赞
举报
russ1122
·2021-11-26
hi
回复
6
举报
收起
- Rustyx:
  hi
  2021-11-26
  回复
  举报
- russ1122:
  hi
  2021-11-26
  回复
  举报
Kaden0204
·2021-11-26
Wow
回复
5
举报
收起
- 55f64d08:
  k
  2021-11-26
  回复
  举报
RyanT2021
·2021-11-26
Hooray
回复
6
举报
收起
- Kaden0204:
  great
  2021-11-26
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-26 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190474385","market":"us","top_or_hot":-1,"title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","media":"Reuters","content":"<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","article_id":"1190474385","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","pubTimestamp":1637924231,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"translate_title":"罗氏股东批准收购诺华207亿美元股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9},"content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":877205404,"gmtCreate":1637932173981,"gmtModify":1637932207028,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877205404","repostId":1190474385,"repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":877685073,"gmtCreate":1637924959111,"gmtModify":1637924959337,"author":{"id":"3566449916340164","authorId":"3566449916340164","name":"russ1122","avatar":"https://static.tigerbbs.com/410e5ecfb4da8e3f85caaaf9808925f2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566449916340164","authorIdStr":"3566449916340164"},"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877685073","repostId":1190474385,"repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6733799,"gmtCreate":1637927784595,"gmtModify":1637927784625,"authorId":3582065337930537,"author":{"id":3582065337930537,"idStr":"3582065337930537","authorId":3582065337930537,"name":"Rustyx","avatar":"https://static.tigerbbs.com/8289642873b5ec03fda36cf3e70cea6d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877685073,"type":1,"supId":0,"prevId":0,"content":"hi","text":"hi","html":"hi"},{"id":6733350,"gmtCreate":1637924964486,"gmtModify":1637924964511,"authorId":3566449916340164,"author":{"id":3566449916340164,"idStr":"3566449916340164","authorId":3566449916340164,"name":"russ1122","avatar":"https://static.tigerbbs.com/410e5ecfb4da8e3f85caaaf9808925f2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877685073,"type":1,"supId":0,"prevId":0,"content":"hi","text":"hi","html":"hi"}],"langContent":"CN"},{"id":877689848,"gmtCreate":1637924342532,"gmtModify":1637924342667,"author":{"id":"4097384260129050","authorId":"4097384260129050","name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4097384260129050","authorIdStr":"4097384260129050"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689848","repostId":1190474385,"repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6733673,"gmtCreate":1637927002573,"gmtModify":1637927002665,"authorId":3575420754880245,"author":{"id":3575420754880245,"idStr":"3575420754880245","authorId":3575420754880245,"name":"55f64d08","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877689848,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"CN"},{"id":877689986,"gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":"3584238171442752","authorId":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3584238171442752","authorIdStr":"3584238171442752"},"htmlText":"Hooray","listText":"Hooray","text":"Hooray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877689986","repostId":1190474385,"repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6733277,"gmtCreate":1637924418357,"gmtModify":1637924418470,"authorId":4097384260129050,"author":{"id":4097384260129050,"idStr":"4097384260129050","authorId":4097384260129050,"name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877689986,"type":1,"supId":0,"prevId":0,"content":"great","text":"great","html":"great"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":54,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}